These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25734961)

  • 21. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 inhibition: current concepts and lessons from human genetics.
    Rodriguez F; Knowles JW
    Curr Atheroscler Rep; 2015 Mar; 17(3):487. PubMed ID: 25637042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.
    Devito F; Zito A; Ricci G; Carbonara R; Dentamaro I; Cortese F; Carbonara S; Ciccone MM
    Pharmacol Res; 2015 Dec; 102():168-75. PubMed ID: 26455563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 inhibitors.
    Gencer B; Lambert G; Mach F
    Swiss Med Wkly; 2015; 145():w14094. PubMed ID: 25856746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9: From discovery to therapeutic applications.
    Farnier M
    Arch Cardiovasc Dis; 2014 Jan; 107(1):58-66. PubMed ID: 24373748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 and lipid lowering drugs.
    Guo YL; Zhang W; Li JJ
    Clin Chim Acta; 2014 Nov; 437():66-71. PubMed ID: 25036764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
    Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
    Basak A; Palmer-Smith H; Mishra P
    Protein Pept Lett; 2012 Jun; 19(6):575-85. PubMed ID: 22519528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 inhibitors--past, present and future.
    Reiner Ž
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
    Davidson MH
    J Clin Lipidol; 2013; 7(3 Suppl):S11-5. PubMed ID: 23642323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.